Interesting. What’s the mechanism about the Oxford one that will do that?
I mean neither to be pedantic nor long-winded. It can be very difficult to distill the nuances of biotechnology into layman’s terms. I will endeavor to do so.
Legacy vaccines are either killed or weakened viruses that can prime the immune system without causing disease. Most of the vaccines you’ve encountered fit into this paradigm.
About a decade ago a new type of vaccine came on the market from Merck. Human Pappilomavirus (HPV) was difficult to culture, so a part of the virus, one of its coat proteins, was cloned, expressed in yeast, purified and used as a vaccine. This was the first subunit vaccine, and has been wildly successful.
Some of the vaccines in Phase 3 trials are so-called mRNA vaccines. Like the HPV vaccine they rely on the expression of a coat protein of the virus. However, these vaccines trick your cells into producing the viral protein to prime the immune system. They deliver an mRNA.
The instructions to make your are encoded in your DNA. When it comes time for the DNA to direct production of a protein (which is one of the main things your DNA does) an mRNA is produced. The mRNA is taken to the site of protein production and directs assembly of the protein.
The mRNA vaccines deliver an artificial mRNA into cells that encodes a viral protein. The idea is the cell makes the viral protein and secretes it. Once in the bloodstream the immune system can react to it and you get your immunity.
It really isn’t as simple as that, since mRNAs are delicate things that are both easily destroyed and unable to enter cells. The mRNAs themselves have been strengthened and packaged into bodies that can penetrate cell membranes. They’ve been working on this a LONG time, but might have at last achieved success. If this works you’re going to see a host of therapeutics based on the concept.
The Oxford vaccine is similar in that it tricks cells to make viral proteins. However, the Oxford vaccine uses a virus to do the delivery. Called Adeno Associated Virus (AAV) it is a gene therapy delivery vector. AAV can persist in cells for a long time, so it can deliver needed proteins stably. And there’s the rub.
I don’t know how long the mRNA’s from mRNA vaccines will persist in cells, I don’t think those data are even available, given that they’re proprietary. I’m willing to bet money not that long, just long enough to make some protein. I suspect the mRNA vaccines are just good enough based on the infancy of the technology.
AAV sticks around, that’s why it works for gene therapy. So you have a cell making a viral proteins for a long time, probably after serum IgM and IgG levels have peaked. Meaning that you have an active immune response against a protein actively being made by cells in the body. The immune system is likely to mistake the cells making that protein as a foreign invader at that point, and react against them. That’s autoimmunity, a Pandora’s box I don’t want to see opened. Moreover, it will take long enough to develop that it could be missed by Phase 3 trials.
I’m by no means an expert virologist, nor will I lay claim to immunological expertise. But the last time I had misgivings about a new therapeutic people died. I hope I’m wrong about this one, in the meantime I won’t be taking it.